The in-vitro activity of drugs against Blastocystis hominis

The development of an assay to measure the sensitivity of drugs against Blastocystis hominis using the incorporation of 3H-hypoxanthine is described. The activity of 42 compounds have been measured. Four of the 5-nitroimidazoles tested (satranida-zole, S75 0400 A, flunidazole and ronidazole) were fo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 1991-04, Vol.27 (4), p.507-516
Hauptverfasser:	Dunn, L. A., Boreham, P. F. L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antiparasitic agents Biological and medical sciences Culture Media Eukaryota - drug effects Eukaryota - metabolism Hypoxanthines - metabolism Medical sciences Microbial Sensitivity Tests Nitroimidazoles - pharmacology Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The development of an assay to measure the sensitivity of drugs against Blastocystis hominis using the incorporation of 3H-hypoxanthine is described. The activity of 42 compounds have been measured. Four of the 5-nitroimidazoles tested (satranida-zole, S75 0400 A, flunidazole and ronidazole) were found to be more active than metronidazole, the drug commonly used to treat infections caused by B. hominis in humans. Other potentially useful compounds include emetine, furazolidone and quinacrine. Ketoconazole and iodoquinol reported to have therapeutic activity in infections caused by this parasite were found to be significantly less active than metronidazole.
ISSN:	0305-7453 1460-2091
DOI:	10.1093/jac/27.4.507